Demir Bilal, Yilmaz Tulay, Guler Emine, Gumus Z Pinar, Akbulut Huseyin, Aldemir Ebru, Coskunol Hakan, Colak Demet Goen, Cianga Ioan, Yamada Shuhei, Timur Suna, Endo Takeshi, Yagci Yusuf
Ege University, Faculty of Science, Biochemistry Department, Bornova, 35100 Izmir, Turkey.
Ege University, Faculty of Science, Biochemistry Department, Bornova, 35100 Izmir, Turkey; Ege University, Institute of Drug Abuse Toxicology & Pharmaceutical Sciences, Bornova, 35100 Izmir, Turkey.
Talanta. 2016 Dec 1;161:789-796. doi: 10.1016/j.talanta.2016.09.042. Epub 2016 Sep 17.
Affinity-type sensors have emerged as outstanding platforms in the detection of diagnostic protein markers, nucleic acids and drugs. Thus, these novel platforms containing antibodies could be integrated into the monitoring systems for abused drugs. Herein, we established a novel detection platform for the analysis of a common illicit drug; methamphetamine (METH). Initially, a fluorescent-labeled polypeptide (EDOT-BTDA-Pala), derived from L-alanine N-carboxyanhydride (L-Ala-NCA) via ring-opening polymerization using 4,7-bis(2,3-dihydrothieno[3,4-b][1,4]dioxin-5-yl)benzo[c][1,2,5]thiadiazole-5,6-diamine (EDOT-NH-BTDA) as initiator, was employed as a glassy carbon electrode (GCE) covering host, in order to immobilize the METH-selective antibody. Prior to the examination of analytical features, GCE/EDOT-BTDA-Pala/Antibody surface was successfully characterized in the way of electrochemical (cyclic voltammetry and electrochemical impedance spectroscopy) and microscopic techniques (scanning electron microscopy and fluorescence microscopy). As for the analytical characterization, linearity and limit of detection (LOD) were found as 10-100µg/mL with an equation of y=0.0429x-0.2347, (R=0.996) and 13.07µg/mL, respectively. Moreover, sample application using artificial urine, saliva and serum samples spiked with METH (10, 25, 50µg/mL) were performed and LC-MS/MS system was used for further confirmation. The described platform can be adapted to monitor the other types of abused drugs by using suitably selected biorecognition elements.
亲和型传感器已成为检测诊断性蛋白质标志物、核酸和药物的出色平台。因此，这些含有抗体的新型平台可集成到滥用药物监测系统中。在此，我们建立了一种用于分析常见非法药物——甲基苯丙胺（METH）的新型检测平台。最初，使用4,7-双（2,3-二氢噻吩并[3,4-b][1,4]二恶英-5-基）苯并[c][1,2,5]噻二唑-5,6-二胺（EDOT-NH-BTDA）作为引发剂，通过L-丙氨酸N-羧基环酸酐（L-Ala-NCA）开环聚合得到的荧光标记多肽（EDOT-BTDA-Pala）被用作玻碳电极（GCE）覆盖主体，以固定METH选择性抗体。在检查分析特性之前，通过电化学（循环伏安法和电化学阻抗谱）和显微镜技术（扫描电子显微镜和荧光显微镜）成功表征了GCE/EDOT-BTDA-Pala/抗体表面。至于分析表征，线性范围和检测限（LOD）分别为10-100μg/mL，方程为y = 0.0429x - 0.2347，（R = 0.996）和13.07μg/mL。此外，使用添加了METH（10、25、50μg/mL）的人工尿液、唾液和血清样本进行了样品应用，并使用LC-MS/MS系统进行进一步确认。通过使用适当选择的生物识别元件，所描述的平台可适用于监测其他类型的滥用药物。
